Ligand Pharmaceuticals Inc (LGDN) – aksjekurser og nyheter

Symboler Symboler	Pris	Endring	Endring (%)	Trend	Forrige pris ved stengetid	Åpne	Høy	Lav	Volum	Markedsverdi
SIXB Materials SIXB Materials	SIXB −0,07%	1 101,37	−0,81	−0,07%	—	1 102,18	1 096,24	1 103,05	1 090,35	—	—
SIXC Communications SIXC Communications	SIXC −0,47%	613,35	−2,89	−0,47%	—	616,24	616,24	617,68	609,10	—	—
SIXE Energy SIXE Energy	SIXE +0,77%	1 198,83	+9,11	+0,77%	—	1 189,72	1 194,74	1 202,79	1 188,58	—	—
SIXI Industrials SIXI Industrials	SIXI +1,75%	1 755,95	+30,26	+1,75%	—	1 725,69	1 730,02	1 762,99	1 730,02	—	—
SIXM Financials SIXM Financials	SIXM −0,79%	638,51	−5,11	−0,79%	—	643,62	643,13	643,17	632,59	—	—
SIXR Staples SIXR Staples	SIXR +1,65%	843,52	+13,73	+1,65%	—	829,79	832,32	845,25	832,32	—	—
SIXRE Real estate SIXRE Real estate	SIXRE +1,19%	215,95	+2,55	+1,19%	—	213,40	213,40	216,07	213,40	—	—
SIXT Technology SIXT Technology	SIXT −1,48%	3 138,91	−47,01	−1,48%	—	3 185,92	3 160,89	3 178,72	3 102,60	—	—
SIXU Utilities SIXU Utilities	SIXU +2,80%	934,37	+25,43	+2,80%	—	908,94	912,57	934,91	912,57	—	—
SIXV Health care SIXV Health care	SIXV −0,10%	1 477,43	−1,53	−0,10%	—	1 478,96	1 478,17	1 482,91	1 466,65	—	—
SIXY Discretionary SIXY Discretionary	SIXY −1,05%	2 380,19	−25,17	−1,05%	—	2 405,36	2 390,34	2 402,53	2 359,18	—	—

LGDN:FRA

Ligand Pharmaceuticals Inc

190,00 €

+0,53%

(+1,00) 1 D

23. apr., 22:00:00 GMT+2 · EUR

Alle symboler

1 D

5 D

1 M

6 M

I år

1 Å

5 Å

MAKS

	Symbol	Pris	Endring	Endring (%)

Genererer viktig statistikk for LGDN …

Åpne

192,00 €

Høy

192,00 €

Lav

190,00 €

Markedsverdi

4,58 mrd.

Snittvolum

2,00

Volum

0,00

52 u høy

195,00 €

52 u lav

87,00 €

Antall ansatte

Nyhetssaker

Fra kilder på nettet

Xã Vĩnh Công

for 2 uker siden

LGND Stock Analysis: Bearish Pressure Amid Market Decline

Profil

Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol. The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments. Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia

Om Ligand Pharmaceuticals Inc

Administrerende direktør-

Ansatte47

Grunnlagtsep. 1987

HovedkontorJupiter, Florida, USA

Sektor-

Nettstedligand.com

Alle verdier i USD	mars 2025	juni 2025	sep. 2025	des. 2025
Inntekt	45,33 mill.	47,63 mill.	115,46 mill.	59,67 mill.
Varekostnad	54,93 mill.	9,47 mill.	24,82 mill.	6,50 mill.
Direkte driftskostnader	54,93 mill.	9,47 mill.	24,82 mill.	6,50 mill.
Utgifter til forskning og utvikling	-	-	-	-
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	18,80 mill.	20,18 mill.	28,45 mill.	25,03 mill.
Driftskostnader	27,06 mill.	28,43 mill.	36,54 mill.	33,12 mill.
Totale driftskostnader	81,99 mill.	37,91 mill.	61,36 mill.	39,63 mill.
Driftsinntekter	−36,66 mill.	9,72 mill.	54,10 mill.	20,04 mill.
Andre ikke-operasjonelle inntekter	−2,06 mill.	96,00k	390,00k	1,48 mill.
EBT inkludert uvanlige elementer	−50,18 mill.	11,22 mill.	141,14 mill.	56,78 mill.
EBT uten uvanlige elementer	−37,81 mill.	10,28 mill.	57,45 mill.	116,80 mill.
Kostnad for inntektsskatt	−7,73 mill.	6,38 mill.	23,86 mill.	12,00 mill.
Faktisk avgiftssats	15,40 %	56,81 %	16,91 %	21,13 %
Andre driftskostnader	-	-	-	-
Nettoinntekt	−42,45 mill.	4,85 mill.	117,27 mill.	44,78 mill.
Netto fortjenestemargin	−93,64 %	10,18 %	101,57 %	75,06 %
Resultat per aksje	1,33	1,60	3,09	2,02
Rente- og investeringsinntekter	1,77 mill.	1,62 mill.	3,87 mill.	6,39 mill.
Rentekostnader	−867,00k	−1,15 mill.	−910,00k	−1,78 mill.
Netto rentekostnader	904,00k	468,00k	2,96 mill.	4,61 mill.
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	−28,35 mill.	17,82 mill.	63,26 mill.	28,25 mill.
Gevinst eller tap ved salg av eiendeler	-	-	-	-

AI-innhold kan inneholde feil. Finn ut mer

HjelpSend tilbakemeldingPersonvern Vilkår Ansvarsfraskrivelse

Finance

Utforskning